Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance

Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance - Medication with mefloquine hydrochloride for progressive multifocal leukoencephalopathy (PML) out of the application range of insurance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023752

Enrollment

Registered

2016-08-24

Start date

2016-04-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

progressive multifocal leukoencephalopathy

Interventions

Oral mefloquine hydrochloride 275mg once a day at first 3 days. Since second week, 275mg in each week oral intake until 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients detected JC virus DNA from cerebrospinal fluid. Patients whose clinical history, neurological examinations, and brain MRI findings are consistent with PML.

Exclusion criteria

Exclusion criteria: Patients allergic to component of this drug. Pregnant or possibly pregnant women. Patients chief or sub investigator diagnose inappropriate.

Design outcomes

Primary

Measure	Time frame
Neurological examination : evaluation by neurologists at starting, 8 weeks, 16 weeks, and 24weeks after administration (or cessation)	—

Secondary

Measure	Time frame
Brain MRI and quantitative JC virus DNA of cerebrospinal fluid : starting, 8 weeks, 16 weeks, and 24weeks after administration(or cessation)	—

Countries

Japan

Contacts

Public ContactKenji Okita

Nagoya City University Department of Neurology

neuron4356@yahoo.co.jp052-853-8094

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026